We highly recommend enabling Javascript while using the BlackBoxRX site.

Tisotumab vedotin-tftv

Ocular Toxicity

  • TIVDAK caused changes in the corneal epithelium and conjunctiva resulting in changes in vision, including severe vision loss, and corneal ulceration. 
  • Conduct an ophthalmic exam at baseline, prior to each dose, and as clinically indicated.
  • Adhere to premedication and required eye care before, during, and after infusion.
  • Withhold TIVDAK until improvement and resume, reduce the dose, or permanently discontinue, based on severity. 

Patient Counseling Information

Medication Guides

Patient Medication Guide - TIVDAK

Package Inserts

Tisotumab Vedotin-tftv

Updated October 2021